Nkarta, Inc.
About Nkarta, Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$104.1M
- Total assets
- $404.2M
- Market cap
- $179.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $122.0M
- Operating income
- -$122.0M
- Income tax
- $0
- Net income
- -$104.1M
- EPS (basic)
- $-1.41
- EPS (diluted)
- $-1.41
Balance sheet
- Total assets
- $404.2M
- Current assets
- $282.5M
- Total liabilities
- $91.9M
- Current liabilities
- $22.3M
- Shareholders’ equity
- $312.3M
Cash flow
- Operating cash flow
- -$88.7M
- Investing cash flow
- $100.3M
- Financing cash flow
- $141.0K
- Net cash flow
- $11.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $179.6M
- EPS (diluted)
- $-1.41
- Shares outstanding
- 74.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 10, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $104.1M in FY2025.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nkarta, Inc..
Write a review
News about Nkarta, Inc.
News & sentiment via Polygon.io
